BioLineRx (BLRX) Return on Capital Employed (2013 - 2025)
BioLineRx (BLRX) recorded quarterly Return on Capital Employed of 36.44% in Q4 2025, up 10.36% quarter-over-quarter from 40.65% in Q3 2025, and up 3065.0% on a YoY basis from 1.15% in Q4 2024.
BioLineRx (BLRX) Return on Capital Employed (2013 - 2025) Analysis & Trends
BioLineRx's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 36.44% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 3065.0% year-over-year to 36.44%; the TTM figure through Dec 2025 stood at 36.44% (up 3065.0% YoY), while the FY2025 annual figure was 37.03%, up 1965.0% from the prior year.
- Return on Capital Employed was 36.44% for Q4 2025 at BioLineRx, up from 40.65% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.99% in Q2 2021 to a low of 318.43% in Q4 2023.
- Historically, Return on Capital Employed has averaged 75.88% across 5 years, with a median of 47.47% in 2022.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 27577 bps in 2023, then soared 25134 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 33.29% in 2021, then declined by 28 bps to 42.66% in 2022, then slumped by 646 bps to 318.43% in 2023, then soared by 79 bps to 67.09% in 2024, then surged by 46 bps to 36.44% in 2025.
- The last three Return on Capital Employed figures came in at 36.44% (Q4 2025), 40.65% (Q3 2025), and 51.98% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -36.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -36.44% |
| Sep 30, 2025 | -40.65% |
| Jun 30, 2025 | -51.98% |
| Mar 31, 2025 | -66.15% |
| Dec 31, 2024 | -67.09% |
| Sep 30, 2024 | -102.50% |
| Jun 30, 2024 | -150.53% |
| Mar 31, 2024 | -173.02% |
| Dec 31, 2023 | -318.43% |
| Sep 30, 2023 | -96.01% |
| Jun 30, 2023 | -66.70% |
| Mar 31, 2023 | -52.81% |
| Dec 31, 2022 | -42.66% |
| Sep 30, 2022 | -41.06% |
| Jun 30, 2022 | -42.96% |
| Mar 31, 2022 | -36.83% |
| Dec 31, 2021 | -33.29% |
| Sep 30, 2021 | -30.52% |
| Jun 30, 2021 | -28.99% |
| Mar 31, 2021 | -38.99% |